QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alvotech-lowers-fy2025-sales-guidance-from-600000m-700000m-to-570000m-600000m-vs-592949m-est

Alvotech (NASDAQ:ALVO) lowers FY2025 sales outlook from $600.000 million-$700.000 million to $570.000 million-$600.000 million ...

 alvotech-q3-eps-002-inline-sales-113744m-miss-117203m-estimate

Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchang...

 alvotech-and-advanz-pharma-receive-uk-mhra-approval-for-gobivaz-biosimilar-across-multiple-indications

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

 deutsche-bank-downgrades-alvotech-to-hold-lowers-price-target-to-8

Deutsche Bank analyst Niall Alexander downgrades Alvotech (NASDAQ:ALVO) from Buy to Hold and lowers the price target from $1...

 alvotech-shares-plunge-33-after-fda-flags-issues

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 rev...

 morgan-stanley-upgrades-alvotech-to-overweight-announces-14-price-target

Morgan Stanley analyst Thibault Boutherin upgrades Alvotech (NASDAQ:ALVO) from Equal-Weight to Overweight and announces $14 ...

 2-advanz-pharma-alvotech-move-closer-to-launching-affordable-asthma-and-allergy-treatment-in-europe-after-ema-filing-acceptance

Advanz Pharma Holdco Limited ("Advanz Pharma"), a UK headquartered global pharmaceutical company with a strategic focus...

 deutsche-bank-upgrades-alvotech-to-buy-announces-14-price-target

Deutsche Bank analyst Niall Alexander upgrades Alvotech (NASDAQ:ALVO) from Hold to Buy and announces $14 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION